Ferumoxytol nanoparticles are being used clinically for the treatment of anemia and molecular imaging in patients. It is well documented that while most patients tolerate ferumoxytol well, a small percentage of patients (i.e., 0.01%) develop severe allergic reactions. The purpose of our proof-of-concept study was to determine whether patients with or without hypersensitivity reactions have specific protein corona profiles around ferumoxytol nanoparticles. In a retrospective, institutional review board approved pilot study, we enrolled 13 pediatric patients (5 girls, 8 boys, mean age 16.9 ± 8.2 years) who received a ferumoxytol-enhanced magnetic resonance imaging and who did (group 1, n = 5) or did not (group 2, n = 8) develop an allergic reaction. Blood samples of these patients were incubated with ferumoxytol, and the formation of a hard protein corona around ferumoxytol nanoparticles was measured by dynamic light scattering, zeta potential, and liquid chromatography–mass spectrometry. We also performed in vitro immune response analyses to randomly selected coronas from each group. Our results provide preliminary evidence that ex vivo analysis of the biomolecular corona may provide useful and predictive information on the possibility of severe allergic reactions to ferumoxytol nanoparticles. In the future, patients with predisposition of an allergic reaction to ferumoxytol may be diagnosed based on the proteomic patterns of the corona around ferumoxytol in their blood sample.

中文翻译：

---

生物分子电晕会引起过敏反应吗？——概念验证研究

Ferumoxytol 纳米颗粒在临床上用于治疗患者贫血和分子成像。有充分证据表明，虽然大多数患者对阿莫西托的耐受性良好，但一小部分患者（即 0.01%）会出现严重的过敏反应。我们概念验证研究的目的是确定患有或不患有超敏反应的患者在费鲁莫托纳米颗粒周围是否具有特定的蛋白质电晕谱。在一项机构审查委员会批准的回顾性试点研究中，我们招募了 13 名儿科患者（5 名女孩，8 名男孩，平均年龄 16.9 ± 8.2 岁），他们接受了费鲁莫托增强磁共振成像，并且接受了检查（第 1 组，n = 5）或没有（第 2 组，n = 8）发生过敏反应。这些患者的血液样本与费鲁莫托一起孵育，并通过动态光散射、zeta 电位和液相色谱-质谱法测量费鲁莫托纳米颗粒周围硬蛋白冠的形成。我们还对每组中随机选择的冠状病毒进行了体外免疫反应分析。我们的结果提供了初步证据，表明生物分子冠的离体分析可以提供有关对费鲁莫托纳米颗粒发生严重过敏反应的可能性的有用和预测信息。将来，可能会根据血液样本中费鲁莫托周围冠的蛋白质组模式来诊断对费鲁莫托有过敏反应倾向的患者。